Stockscreener 앱 받기
60.66
1.92%
1.14
전일 마감가:
$59.52
열려 있는:
$61.22
하루 거래량:
238.78K
Relative Volume:
0.89
시가총액:
$595.20M
수익:
-
순이익/손실:
$-19.80M
주가수익비율:
-24.83
EPS:
-2.4426
순현금흐름:
$-14.56M
1주 성능:
-1.48%
1개월 성능:
-19.12%
6개월 성능:
-23.10%
1년 성능:
+115.18%
1일 변동 폭
$59.00
$62.55
1주일 범위
$56.47
$63.34
52주 변동 폭
$23.18
$123.75
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
Compare DRUG vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DRUG
Bright Minds Biosciences Inc
|
60.66 | 595.20M | 0 | -19.80M | -14.56M | -2.4426 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-13 | 개시 | Jefferies | Buy |
| 2025-09-08 | 개시 | BTIG Research | Buy |
| 2025-05-13 | 개시 | TD Cowen | Buy |
| 2025-05-07 | 개시 | Chardan Capital Markets | Buy |
| 2025-01-23 | 개시 | Piper Sandler | Overweight |
| 2025-01-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-01-10 | 개시 | H.C. Wainwright | Buy |
| 2024-11-26 | 개시 | Robert W. Baird | Outperform |
모두보기
Bright Minds Biosciences Inc 주식(DRUG)의 최신 뉴스
Bright Minds Biosciences Inc (DRUG) Institutional Confidence - TradingKey
Bright Minds Biosciences Inc (DRUG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bright Minds Biosciences Inc (DRUG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bright Minds Biosciences Inc (DRUG) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bright Minds Biosciences Inc (DRUG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bright Minds Biosciences Inc - TradingKey
Bright Minds Biosciences Inc (DRUG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bright Minds Biosciences Inc (DRUG) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bright Minds Biosciences (DRUG) Slides 1% as Buyers and Sellers Battle Near Critical LevelsBull Flag - newsline.com
Behavioral Patterns of DRUG and Institutional Flows - Stock Traders Daily
Bright Minds Biosciences (DRUG) Surges 3.86% as Shares Test Key Resistance ZoneMomentum Trade - newsline.com
News Releases for Bright Minds Biosciences Inc. - The Canadian Securities Exchange (CSE)
Bright Minds Biosciences Dips 4.28% as Biotech Volatility ResurfacesOpening Range Breakout - newsline.com
Bright Minds Biosciences Sets March 31, 2026 AGM, Files Meeting Materials on Form 6-K - TipRanks
Bright Minds Biosciences (NASDAQ: DRUG) details 2026 AGM, board nominees and auditor - Stock Titan
H.C. Wainwright reiterates Bright Minds stock rating on epilepsy data - Investing.com UK
Bright Minds Biosciences Sets March 31, 2026 Date for Annual General Meeting - TipRanks
Bright Minds (DRUG) outlines 2026 AGM in Vancouver with key record dates - Stock Titan
H.C. Wainwright Maintains Bright Minds Biosciences(DRUG.US) With Buy Rating, Maintains Target Price $145 - Moomoo
H.C. Wainwright reiterates Bright Minds stock rating on epilepsy data By Investing.com - Investing.com South Africa
DRUG Reiterated by HC Wainwright & Co. -- Price Target Maintained at $145 - GuruFocus
(DRUG) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Bright Minds Biosciences to Present at Jefferies Healthcare Conference and Grants New Stock Options - TipRanks
Bright Minds Biosciences (NASDAQ: DRUG) grants 109,000 options and sets June 3 Jefferies talk - Stock Titan
Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference - Weekly Voice
Bright Minds, a biotech targeting epilepsy, to speak at Jefferies health event - Stock Titan
Bright Minds Biosciences (DRUG) Edges Higher Amid Consolidation Near Key Support LevelLiquidity Order Flow - newsline.com
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline - AOL.com
B Group Discloses New Position in Bright Minds Biosciences - HarianBasis.co
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline - The Motley Fool
Bright Minds Biosciences Stock Jumps After $220 Piper Sandler Call—What DRUG Traders Are Watching - Bez Kabli
Piper Sandler raises Bright Minds stock price target on program progress - Investing.com UK
Piper Sandler Maintains Bright Minds Biosciences(DRUG.US) With Buy Rating, Raises Target Price to $220 - Moomoo
Piper Sandler raises Bright Minds stock price target on program progress By Investing.com - Investing.com South Africa
Bright Minds Biosciences Boosts Cash Reserves as R&D Losses Widen in Q2 2026 Filing - TipRanks
[6-K] BRIGHT MINDS BIOSCIENCES INC. Current Report (Foreign Issuer) | DRUG SEC FilingForm 6-K - Stock Titan
Vestal Point (DRUG) and Ryan Wilder report 492,319 shares, 5% stake - Stock Titan
Janus Henderson (DRUG) discloses 1.28M shares, 13.1% stake - Stock Titan
Janus Henderson Group (DRUG) discloses 1.28M shares, 13.1% stake - Stock Titan
Bright Minds Biosciences Inc. (DRUG) Eps Diluted (TTM) - Zacks Investment Research
Vivo entities disclose 504,645 shares in Bright Minds Biosciences (DRUG) - Stock Titan
TradingKey - TradingKey
Bright Minds Biosciences Inc expected to post a loss of C$1.19 a shareEarnings Preview - TradingView
Bright Minds Biosciences (DRUG) to Release Earnings on Friday - MarketBeat
Trading Systems Reacting to (DRUG) Volatility - Stock Traders Daily
This Insider Has Just Sold Shares In Bright Minds Biosciences - simplywall.st
DRUG SEC FilingsBright Minds Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cormorant sells $9.78m in Bright Minds Biosciences stock - Investing.com UK
Bright Minds Biosciences Inc (DRUG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):